Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a decline of 11.89% over the past month, an increase of 13.46% over the past three months, and a year-to-date increase of 8.75% [1] - The index consists of 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The index is based on a starting point of 1000.0 points as of December 31, 2018 [1] Group 2 - The top ten weighted companies in the index include WuXi Biologics (15.72%), JD Health (11.24%), Alibaba Health (7.31%), Sinopharm (5.92%), WuXi AppTec (5.0%), Kingstar BioTech (3.88%), Weigao Group (3.72%), CanSino Biologics (2.43%), MicroPort Medical (2.4%), and Innovent Biologics (2.35%) [1] - The index is exclusively composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - The industry composition of the index includes 35.98% in medical services, 30.61% in pharmaceuticals and biotechnology, 12.17% in medical devices, 10.73% in chemical drugs, 10.09% in biological drugs, and 0.42% in traditional Chinese medicine [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers and acquisitions [2]

Core Viewpoint - The China Securities Hong Kong Biotechnology Theme Index has shown a mixed performance, with a recent decline but a notable increase over the past three months and year-to-date [1][2] Group 1: Index Performance - The China Securities Hong Kong Biotechnology Theme Index reported a value of 1155.57 points, with a decline of 4.92% over the past month, an increase of 20.52% over the past three months, and a year-to-date increase of 13.66% [1] - The index is composed of 50 listed companies in the fields of biopharmaceuticals, pharmaceuticals, and biotechnology services, reflecting the overall performance of biotechnology theme stocks listed in Hong Kong [1] Group 2: Index Composition - The top ten weighted companies in the index are: BeiGene (15.21%), WuXi Biologics (11.43%), Innovent Biologics (10.19%), CanSino Biologics (7.71%), CSPC Pharmaceutical Group (6.08%), China Biologic Products (5.62%), Hansoh Pharmaceutical (3.77%), Zai Lab (3.43%), 3SBio (3.27%), and WuXi AppTec (2.83%) [1] - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3: Industry Breakdown - The industry composition of the index shows that biopharmaceuticals account for 52.79%, chemical drugs for 24.55%, pharmaceutical and biotechnology services for 18.85%, and medical devices for 3.81% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]